The Stiller Centre
700 Collip Circle Suite 114
London, ON N6G 4X8
Industry: Medical Devices
Full Time Employees:
|Dr. Philip M. Toleikis||Pres, CEO & Director||286.61k||N/A||N/A|
|Mr. David Swetlow C.A., CPA, C.A||Chief Financial Officer||143.3k||N/A||N/A|
|Mr. Douglas Maret||Chief Science Officer||N/A||N/A||N/A|
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
Sernova Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.